An enzymatic route to selenazolines by Koehnke, Jesko et al.
DOI: 10.1002/cbic.201300037
An Enzymatic Route to Selenazolines
Jesko Koehnke,[a] Falk Morawitz,[a] Andrew F. Bent,[a] Wael E. Houssen,[b, c] Sally L. Shirran,[a]
Matthew A. Fuszard,[a] Iain A. Smellie,[a] Catherine H. Botting,[a] Margaret C. M. Smith,[b]
Marcel Jaspars,*[c] and James H. Naismith*[a]
Selenium heterocycles (e.g. , selenazofurin) have a number of
potential applications in medicinal chemistry ; although isoste-
ric with sulfur and oxygen, they have different chemical prop-
erties. As a route to exploring biological properties, this substi-
tution is a valuable addition to the chemist’s arsenal. The
chemical synthesis of selenazolines and selenazoles involves
the use of stoichiometric quantities of toxic selenium-contain-
ing precursors. However, we have incorporated selenocysteine
into a substrate ribosomal peptide by feeding dilute solutions
of selenocysteine to E. coli. We demonstrate that the dehydrat-
ing heterocyclases from the patellamide and the closely related
trunkamide biosynthetic pathways process selenocysteine-con-
taining substrate to yield selenazoline, thus establishing an en-
zymatic route to selenazolines. Such groups can also be incor-
porated into macrocyclic peptides. Although this remains un-
known, it is possible that nature itself could utilise the same
enzymes to produce selenium variants of natural products.
1,3-Selenazoles are intriguing structural motifs in medicinal
chemistry[1] as they serve as analogues of the corresponding
thiazoles; arguably the best-known examples are the synthetic
compounds selenazofurin[2] (1) and amselamine[3] (2 ;
Scheme 1). Zhang et al.[4] recently reported the chemical syn-
thesis of selenazole-containing cyclic peptides (e.g. , 3) and
their application in X-ray diffraction studies of P-glycoprotein.
1,3-Selenazolines[1a] have also received attention in recent
years,[5] for example, Withers et al.[5a] have reported the synthe-
sis of a GlcNAc-derived 1,3-selenazole that was evaluated as
a potential O-GlcNAcase inhibitor. Most synthetic routes to 1,3-
selenazoles are based on the Hantzsch synthesis,[1a,5c,6] al-
though other methods have been investigated.[7]
Cyanobactins are a family of ribosomally derived cyclic pep-
tides containing six to 20 amino acids, they are produced from
a larger precursor peptide and contain extensive chemical
modifications including heterocycles, d-stereocentres and di-
sulfide bonds. They are potent biological scaffolds that can
cross cell membranes and are resistant to enzymatic degrada-
tion.[8] Patellamides are members of the cyanobactin family
that are produced by Prochloron didemni, an obligate symbiont
of the sea squirt Lissoclinum patella found in Pacific reefs.[9] The
biosynthetic pathway involves the ATP-dependent heterocy-
clase PatD, protease PatA and oxidase/macrocyclase PatG,
which convert the ribosomal precursor peptide PatE into the
final macrocycle (Scheme 2). Patellamides and variants can be
Scheme 1. Structures of selenazofurin (1), amselamine (2) and the chemically
synthesised patellamide-like QZ60-SSSS (3).
Scheme 2. Cassette residues of the precursor peptide PatE are heterocycl-
ised by PatD. The leader peptide is needed for processing but is subse-
quently cleaved off by PatA. The timing and cause (enzymatic or spontane-
ous) of epimerisations are not known. PatG oxidises the thiazoline, cleaves
off the AYDGE from the C terminus and macrocyclises the eight-residue pep-
tide to give the final product patellamide D (4).
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produced heterologously in E. coli by coexpressing a mutant
PatE with the biosynthetic genes.[10]
Herein we describe the biosynthesis of a selenol-containing
PatE from selenocysteine (SeCys). SeCys is commercially avail-
able and significantly less toxic than many other selenium pre-
cursors. We show that the selenium variant protein is a sub-
strate for PatD (and its homologue from the trunkamide path-
way, TruD),[9, 10] which heterocyclises cysteine residues to thia-
zolines. This enzymatic route thus offers a mild and convenient
laboratory method for the synthesis of selenazoline (Sezn)
within the context of a peptide.
We purified a modified PatE[9] precursor peptide that has
a single product cassette containing the sequence ITASITFC
and in which the cysteine is replaced by SeCys by using the
medium supplementation method. We confirmed the incorpo-
ration of Se by mass spectrometry and denoted the product
PatE(Se). We also observed PatE in which the selenol was hy-
drolysed to serine (PatE(O), 6828.6 Da, Figure 1); presumably
this is a consequence of the growth and protein purification
process. Selenol (like thiol) reacts with iodoacetamide (IAA) to
give a covalent adduct, as can be seen in Figure 1. We rea-
soned that addition of IAA to TruD-treated PatE, which has
heterocyclic Sezn, would not lead to a reaction, and thus no
mass shift would be seen. We saw that PatE that had reacted
with TruD (and PatD), and thus lost a water molecule, no
longer reacts with IAA (Figure 1); this is consistent with loss of
selenol reactivity as the result of formation of a heterocycle.
We digested TruD- and PatD-treated PatE(Se) with the pro-
tease GluC, which cleaves after acid residues, to produce small-
er molecules for more precise analysis. GluC treatment yielded
ASITASITF(Sezn)AYDGELE but did not cleave between C-termi-
nal E and L, possibly because the preceding Sezn heterocycle
inhibited proteolysis. For the TruD-treated PatE(Se), we ob-
served a doubly charged fragment of m/z 910.8847 that has
the expected isotope pattern for the incorporation of selenium
into the molecule and matches the predicted mass of
ASITASITF(Sezn)AYDGELE (+6.5 ppm; Figure 2A).
For the PatD-processed PatE(Se), we observed a doubly
charged fragment of 892.8717 Da with a selenium isotope pat-
tern that matches ASITASITF(SeCys)AYDGELE with three hetero-
cycles (+4.0 ppm; Figure 2B). Proteolytic fragments were ana-
lysed by MS/MS, and the peptide sequences were determined
by analysing the internal cleavage, b- and y-ion series (Fig-
ure S1A and B). We were able to sequence the peptides to
within one residue of the expected Sezn on both the N- and
C-terminal side. The remaining three-residue fragment
(F(Sezn)A) is 18 Da lighter than expected for an unmodified
peptide containing SeCys. Although the TruD-treated peptide
gave extensive ion series to the N terminus, the PatD-treated
peptide with multiple heterocycles could only be sequenced
by combining multiple ion series (Figure S1A and B).
We repeated the experiment by using a different PatE(Se)
with the cassette sequence ITACITFC and observed (mass spec-
trometry) Se incorporation. After heterocyclisation with TruD,
we treated the resulting peptide with protease to yield the
peptide ITA(Sezn)ITF(Sezn)AYDGE, which was then macrocy-
clised with purified PatG[11] in vitro, as previously described.[11]
The macrocycle has the expected mass for two Se atoms (Fig-
Figure 1. MALDI spectra of PatE(Se), after treatment with iodoacetamide
(IAA), incubation with TruD, incubation with TruD followed by IAA, incuba-
tion with PatD and incubation with PatD followed by IAA. PatE(Se) shows
both Se- (6891.4 to 6949.0 Da) and S- (6844.7 Da to 6901.6 Da) containing
compounds. IAA reacts with free selenols (and thiols) adding 57 Da. TruD in-
cubations show loss of 18 Da (one heterocyclisation), PatD loss of 36 and
54 Da (two and three heterocyclisations). After TruD or PatD treatment, IAA
has no effect, thus indicating that free selenol/thiol is no longer present in
the molecule. Molecules and expected weights are detailed in Table S1.
Figure 2. A) Doubly charged ASITASITF(Sezn)AYDGELE, expected m/z
910.8787 Da (+6.5 ppm) with the characteristic Se isotope pattern.
B) Doubly charged ASITF*S*IT*F(Sezn)AYDGELE with three heterocycles
(PatD processes alcohols, we cannot assign which of the alcohols (marked
by *) are processed in addition to SeCys, more detail in Table S3), expected
m/z 892.8681 (+4.0 ppm). C) Macrocyclised ITA(Sezn)ITF(Sezn) (5), expected
m/z 913.2627 (+3.1 ppm).
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ure 2C), and fragmentation analysis (Figure S2) confirmed the
macrocycle structure. PatG will only macrocyclise a peptide
with a heterocycle (or Pro) immediately N-terminal to the
AYDGE motif.[12] Taken together, these data establish that TruD
and PatD are capable of heterocyclising SeCys.
The heterocyclisation reaction of SeCys by PatD or TruD was
complete in 30 min. This is a similar time frame to the reaction
of the natural substrate, thus indicating that SeCys is a suitable
substrate for PatD/TruD. The reaction has been proposed to
proceed through nucleophilic attack of the XH on the adja-
cent amide to form a hemiorthoamide intermediate.[13] This
intermediate attacks the g-phosphate of ATP to form a phos-
phorylated hemiorthoamide, which subsequently decomposes
to thiazoline and inorganic phosphate. Se is considered to be
more nucleophilic than S or O therefore it should be more
reactive if hemiorthoamide formation is rate limiting. We lack
a robust assay to detect changes in rate of less than an order
of magnitude and suggest any effect is within this range for
the SeCys variant.
Sezn compounds might have different biological as well as
chemical properties from their oxygen and sulfur relatives.
Their widespread testing and thus exploitation have been lim-
ited by the difficulty of producing them in the laboratory. An
enzymatic route from commercially available SeCys is a relative-
ly benign method for the production of Sezn-containing natu-
ral products. Such Sezn variants could be directly useful or
form part of larger synthetic schemes. Furthermore, as many
natural products contain thiazolines/thiazoles or oxazolines/
oxazoles and thus a heterocyclase is used during biosynthesis,
one can envisage biosynthetic routes to Se variants of several
natural products. Where the pathway can be reconstituted in
E. coli, production of SeCys variants can be trivially accom-
plished by medium supplementation; this enables production
by both ribosomal and nonribosomal peptide systems. Where
microorganisms other than E. coli have to be used, either
growth medium can be supplemented with SeCys (akin to
E. coli) or SeCys-containing peptide substrate (made either syn-
thetically or in E. coli) can be added to crude extract or purified
proteins.
It has been reported that ~25% of sequenced prokaryotic
genomes contain the genes necessary for selenocysteine bio-
synthesis.[14] The demonstration that two heterocyclases can
process SeCys raises the prospect of significant numbers of
selenium-containing peptide-derived natural products to be
discovered.
Experimental Section
We constructed a modified PatE that has a single eight-residue
(ITASITFC) product cassette and is flanked by the normal leader se-
quence and macrocyclisation tag. A C-terminal His-tag was added
to the construct to aid purification. The construct was over ex-
pressed in E. coli in minimum medium supplemented with seleno-
cysteine (100 mgL1), as described by Salgado et al.[15] The final
yield of purified PatE(Se) was 22 mg per litre of bacterial culture.
Analysis of the protein by mass spectrometry showed that the
incorporation of SeCys ranged from 60 to 100% (estimated by
MALDI). Usually, we obtained ~75% incorporation, and the protein
was a mixed PatE sample containing the SeCys-incorporated
PatE(Se) (6891.4 Da) and cysteine (denoted PatE(S), 6844.7 Da), al-
though on occasion we were able to obtain 100% Se substitution.
The expression conditions are described further in the Supporting
Information.
PatE(Se) was treated with purified TruD (100 mm PatE, 5 mm TruD,
5 mm ATP, 5 mm MgCl2, 150 mm NaCl, 10 mm HEPES, pH 7.4, 1 mm
tris-(2-carboxyethyl)phosphine hydrochloride (TCEP), 30 min at
37 8C) and both PatE(Se) and PatE(S) lose 18 Da; this is consistent
with the dehydrative heterocyclisation of cysteine and selenocys-
teine (Figure 1). We incubated PatE(Se) and PatE(S) with iodoaceta-
mide (IAA) and analysed the products by mass spectrometry
(Figure 1). IAA forms a covalent adduct with free thiol or selenol,
thereby adding 57 Da to the molecular weight (Figure 1 and
Table S1). After treatment of PatE(Se) with TruD there is no change
in mass upon addition of IAA (Figure 1), thus indicating that the
free selenol has been consumed. We repeated the experiment with
both PatE(Se) and PatE(S), but with PatD replacing TruD. Under the
same experimental conditions, we observed losses of 36 and 54 Da
(two and three water molecules, respectively) for both, thus indi-
cating incomplete heterocyclisation (Figure 1). Addition of IAA
after PatD incubation did not result in a mass shift ; thus suggest-
ing that the thiol of PatE(S) and selenol of PatE(Se) were complete-
ly heterocyclised. This would imply incomplete heterocyclisation of
the alcohols by PatD.
Intact protein mass was determined by LC-ESIMS on a Waters 2795
HPLC and Waters LCT MS. Sample (20 mL, ca. 50 mm) was injected
onto a Waters Massprep column (2.15.0 mm). The sample was
washed with water/acetonitrile (ACN) with 1% formic acid (95:5)
for 5 min to desalt the protein and eluted with a gradient from
95:5 to 5:95 over 5 min. Then the column was returned to the ini-
tial conditions and reequilibrated for 10 min. Positive ionisation
ESI-MS was carried out with scanning from m/z 500 to 2500 in 1 s
at a capillary voltage of 3500 V and cone voltage of 30 V by using
an RF lens of 500 Hz and Waters Masslynx v. 4.0 software. Multiply
charged ion series were transformed to mass data by using the
MaxEnt I deconvolution program over a range of 6000–8000 Da at
a resolution of 0.1 Da with peak width at half height on the most
intense peak in the charged ion series.
Peptides were separated by using a nanoLC Ultra 2D plus loading
pump and nanoLC AS-2 autosampler equipped with a nanoflex
cHiPLC chip-based chromatography system (Eskigent, Dublin, CA),
loaded with a ChromXP C18-CL trap and column (Eskigent, Dublin,
CA). The peptides were eluted with a gradient of increasing ACN
concentration in water, containing 0.1% formic acid (5–35% ACN
over 45 min, 35–50% over a further 3 min, followed by 95% ACN
to clean the column, before re-equilibration with 5% ACN). The
eluents were then sprayed into an ABSciex 5600 TripleTOF instru-
ment (ABSciex, Foster City, CA). Product ion scans of the target
masses of 892.9, 901.9 and 910.9 Da were acquired with a TOF MS/
MS range of 95–2000 Da with 0.5 s acquisition cycle time at unit
resolution and also at open resolution to observe the Se isotope
pattern. Ion spray voltage was set to 2500 V, declustering potential
was set at 100 V, and collision energy was set at 65 V with
a spread of 15 V. The spectra obtained were manually inspected by
using PeakView 1.2 software (ABSciex).
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